Read Gene SA

Read Gene SA has a current ratio of 10.28, indicating strong liquidity with current assets significantly outpacing current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating and net income, with operating cash flow of 164,270 PLN and free cash flow of -390,260 PLN, indicating cash flow challenges despite strong liquidity. Profitability metrics show a return on equity of -14.32% and a return on assets of -3.64%, both significantly below the industry median for biotechnology firms. The company's operating margin is -25.63% (calculated as operating income / revenue), and its net margin is -23.84% (calculated as net income / revenue), both of which are negative and suggest operational inefficiencies or high costs relative to revenue. Read Gene SA operates in a single business segment, with all revenue derived from its biotechnology and medical research activities. The company does not disclose geographic revenue breakdowns, but its operations are likely concentrated in its home market. This lack of geographic diversification could expose the company to regional economic or regulatory risks. The company's revenue for the latest period was 2,119,010 PLN, with no disclosed revenue growth in the prior period. The outlook for the current fiscal year is neutral, with no significant revenue growth expected. The next fiscal year is also projected to show minimal change, with no clear drivers of growth identified in the financial data. Risk factors include low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has no long-term debt and a strong current ratio, but its negative operating and net income suggest potential cash flow constraints. There is no indication of dilution risk in the near term, as shares outstanding for both basic and diluted are the same. Recent events include the latest financial filing, which shows a continuation of losses and negative cash flow from operations. No significant events such as mergers, acquisitions, or major regulatory changes were disclosed in the latest filing. The company's financial performance remains a key area of focus for investors.